AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01405430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab + blood samples
Description: Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.
Study NCT02013830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle.
Study NCT02013830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
Study NCT03840499 — intervention group
Intervention type: DRUG
Intervention: Optimal medical therapy
Description: Optimal medical therapy
Study NCT02322788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline sulphate
Description: Bricanyl Turbuhaler M2
Study NCT02322788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline sulphate
Description: Bricanyl Turbuhaler M3
Study NCT02322788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for terbutaline sulphate
Description: Placebo Turbuhaler M2
Study NCT02322788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for terbutaline sulphate
Description: Placebo Turbuhaler M3
Study NCT03170388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: Gel
Study NCT03170388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component A
Description: Component A
Study NCT03170388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component B
Description: Component B
Study NCT03170388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component C
Description: Component C
Study NCT03170388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: Vehicle Gel
Study NCT02497794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chew gum
Description: The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
Study NCT02497794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chew gum
Description: The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
Study NCT03328728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP HA Kit
Description: Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
Study NCT03328728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
Study NCT00970255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual Frenulum frenotomy
Description: Clipping the lingual frenulum with scissors
Study NCT00970255 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham frenotomy
Description: Sham Clipping the lingual frenulum with scissors
Study NCT01317784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV, HCV, HBV, and syphilis
Description: Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
Study NCT01317784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV/HCV
Description: Choice of 10 different tests for HIV and hepatitis C.
Study NCT01317784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV/syphilis
Description: Choice of 7 different tests for HIV and syphilis
Study NCT01317784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV only
Description: Choice of 4 different tests for HIV only.
Study NCT04403763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop
Study NCT04403763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical eye drop
Study NCT00920257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK2141795 is an oral AKT inhibitor.
Study NCT03981042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed
Study NCT01064817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Study NCT01064817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Study NCT01045707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
Study NCT01045707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study NCT00918918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol + orange juice
Description: 100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
Study NCT00918918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: 200 mL orange juice
Study NCT03416491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-136
Description: KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
Study NCT03416491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir was provided in a single tablet of 400 mg.
Study NCT01139749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin
Description: capsules of 20 mg a day, every other day, for six months
Study NCT01139749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salicylic acid and ciclopirox olamine
Description: Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
Study NCT02588547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: IV granisetron 1 mg before spinal anethesia
Study NCT02588547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: IV granisetron 0.7 mg before spinal anethesia
Study NCT02588547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: IV 2 ml 0.9 sodium chloride before spinal anethesia
Study NCT04216420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERM-observed self-administered therapy
Description: The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
Study NCT03226119 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MP Diagnostics HTLV Blot 2.4
Description: HTLV I/II Confirmation and Differentiation
Study NCT03271606 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
Study NCT03271606 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional measures
Description: The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
Study NCT00111358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Study NCT01438086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mecasermin
Description: Intracoronary bolus
Study NCT01438086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride injection
Description: Intracoronary bolus
Study NCT02105064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
Study NCT02105064 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM rTMS
Description: Sham rTMS, without brain stimulation
Study NCT04807322 — intervention group
Intervention type: PROCEDURE
Intervention: Reverse Total Shoulder Arthroplasty (RTSA)
Description: Implantation of a Reverse Total Shoulder Arthroplasty
Study NCT01980121 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
Study NCT03973684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pdt experimental group
Description: G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
Study NCT03973684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pdt experimental group
Description: G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
Study NCT01272427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose
Description: 0.75 g/kg body weight of glucose added to water
Study NCT01272427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water and whey protein
Description: 0.75 g/kg body weight of whey protein added to water
Study NCT01272427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with noncaloric sweetener
Description: 0.15 g of sucralose added to water
Study NCT00675246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
Study NCT00003516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study NCT00307463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: strict volume control policy
Description: strict volume control by UF and dietary salt restriction
Study NCT00307463 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: antihypertensive drugs administration
Description: continue antihypertensive medications
Study NCT02613871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT00959582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: 18-F-FDG PET/CT and Volumetric CT
Description: Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
Study NCT02296424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885 150 mg (Canakinumab)
Description: Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
Study NCT03901937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ω-3 polyunsaturated fatty acid
Description: CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
Study NCT03901937 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intestinal surgery for Crohn's Disease
Description: Patients receive bowel resection due to complications of Crohn's Disease
Study NCT00111358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No lifestyle modification
Study NCT03269799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500 MG Oral Capsule
Description: non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
Study NCT03269799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: non surgical periodontal treatment+placebo for 2 months
Study NCT01766791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise, low repetition range
Description: High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
Study NCT01766791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise, high repetition range
Description: High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
Study NCT01766791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise with protein
Description: High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
Study NCT01766791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group, no intervention, maintenance of physical activity
Study NCT02229565 — intervention group
Intervention type: DEVICE
Intervention: Biopsy or prostatectomy
Study NCT01612884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel
Description: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Study NCT01612884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
Study NCT02668094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02668094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study NCT02668094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT00908557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: readability improvement and good practice redaction
Description: improvement using Flesch readability index and good practice in redaction of informed consent documents.
Study NCT00908557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: information based on the classic informed consent document
Study NCT01099488 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood withdrawal
Description: Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
Study NCT03276442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Description: Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
Study NCT03276442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat dietary intervention
Description: High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
Study NCT04546789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 (BTK inhibitor)
Description: Participants will receive a single oral dose of M2951 (BTK inhibitor).
Study NCT00791648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.
Study NCT00791648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1.
Study NCT03901937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal surgery for Crohn's Disease
Description: Patients receive bowel resection due to complications of Crohn's Disease
Study NCT03565523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: Containing 385 mg nitrate
Study NCT03565523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: \<0.1 mmol nitrate in sucrose solution with beet coloring
Study NCT04670159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.